Intra-Cellular Therapies
ITCI
#1759
Rank
โ‚น809.60 B
Marketcap
โ‚น7,637
Share price
1.20%
Change (1 day)
63.14%
Change (1 year)

Revenue for Intra-Cellular Therapies (ITCI)

Revenue in 2024 (TTM): โ‚น51.13 Billion

According to Intra-Cellular Therapies's latest financial reports the company's current revenue (TTM ) is โ‚น51.70 Billion. In 2023 the company made a revenue of โ‚น38.47 Billion an increase over the revenue in the year 2022 that were of โ‚น20.61 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Intra-Cellular Therapies from 2014 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) โ‚น51.13 B32.9%
2023 โ‚น38.47 B86.63%
2022 โ‚น20.61 B238.98%
2021 โ‚น6.08 B269.08%
2020 โ‚น1.64 B38021.74%
2019 โ‚น4.32 M
2018 N/A
2017 N/A
2016 N/A-100%
2015 โ‚น2.03 M-94.13%
2014 โ‚น34.7 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚น84.37 M-99.84%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น0.85 B-98.34%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น11.27 B-78.19%๐Ÿ‡บ๐Ÿ‡ธ USA